Skip to Content

Yervoy Approval History

  • FDA approved: Yes (First approved March 25th, 2011)
  • Brand name: Yervoy
  • Generic name: ipilimumab
  • Dosage form: Injection
  • Company: Bristol-Myers Squibb
  • Treatment for: Melanoma, Metastatic

Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma.

Development History and FDA Approval Process for Yervoy

DateArticle
Oct 28, 2015Approval FDA Approves Yervoy to Reduce the Risk of Melanoma Returning after Surgery
Mar 28, 2011Approval FDA Approves Yervoy for Late-Stage Melanoma
Nov  2, 2010Bristol-Myers Squibb Announces that the U.S. Food and Drug Administration Has Extended the Review Timeline for the Ipilimumab Biologics License Application
Aug 18, 2010Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide